Your browser doesn't support javascript.
loading
Update on the use of FDG-PET/CT in malignant lymphoma.
Terauchi, Takashi.
Afiliación
  • Terauchi T; Japanese Foundation for Cancer Research Department of Nuclear Medicine, Cancer Institute Hospital.
Rinsho Ketsueki ; 57(10): 2008-2012, 2016.
Article en Ja | MEDLINE | ID: mdl-27795508
This article aims to explain the current status of FDG-PET/CT in malignant lymphoma management by reviewing the new recommendations for evaluation, staging, and response assessment in patients with malignant lymphoma, published as the Lugano Classification in 2014. FDG-PET/CT was formally incorporated into standard staging for FDG-avid lymphoma in this new classification. Nearly all subtypes of malignant lymphoma are FDG-avid. In staging, the increased FDG uptake compatible with lymphoma is considered to represent involvement of lymphoma, regardless of size, and the FDG-avid lesion is potentially a good biopsy target. FDG-PET/CT is more sensitive than bone marrow biopsy in diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). Location, size and FDG uptake, based on a 5 point scale (compared to hepatic uptake and mediastinal blood pool) for the residual lesion, constitute useful information for response assessment. Routine surveillance scans after remission are discouraged, especially for DLBCL and HL. Interim PET is regarded as a promising biomarker for stratifying treatments of malignant lymphoma, although its usefulness remains controversial.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Tomografía Computarizada por Tomografía de Emisión de Positrones Tipo de estudio: Guideline Límite: Humans Idioma: Ja Revista: Rinsho Ketsueki Año: 2016 Tipo del documento: Article
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Tomografía Computarizada por Tomografía de Emisión de Positrones Tipo de estudio: Guideline Límite: Humans Idioma: Ja Revista: Rinsho Ketsueki Año: 2016 Tipo del documento: Article